Revenue segments as reported by the company.

Product sales

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Acquired in-process research and development

Selling, general and administrative

Other

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Amgen

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, Aimovig, KANJINTI, EVENITY, AMGEVITA, AVSOLA, BLINCYTO, MVASI, Corlanor, Enbrel, EPOGEN, IMLYGIC, Kyprolis, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, Otezla, RIABNI, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Amgen reports robust Q4 results, navigates pricing challenges for growth

Amgen's Q4 earnings call highlighted strong performance, innovative products, and strategic acquisitions driving growth. Challenges in pricing strategies and market dynamics require careful navigation. Opportunities in promising data, asset advancements, and access strategies position Amgen for future success.

Amgen reports robust Q1 performance, eyes growth in Asia-Pacific

Amgen's Q1 2023 earnings call highlighted strong performance, innovative R&D focus, and growth in key markets like Asia-Pacific.
Despite challenges with inventory issues and pricing dynamics, the company remains optimistic about long-term growth opportunities and biosimilar competitiveness.
Opportunities lie in addressing complex disorders like obesity, expanding market presence, and driving growth in key product franchises.
Overall, Amgen's strategic focus on performance, international expansion, and pipeline advancements positions the company for sustained growth and innovation.

Amgen reports robust Q2 earnings, eyes growth through strategic acquisitions

Amgen's strong Q2 performance, robust sales growth, and strategic acquisitions position the company for continued success.
While facing challenges in competitive markets and potential legal risks, Amgen's focus on innovation and portfolio expansion presents growth opportunities.
With a solid financial outlook, increased R&D investments, and a focus on shareholder returns, Amgen remains well-positioned for future growth.
Updates on key products, positive trial results, and strategic initiatives underscore Amgen's commitment to advancing healthcare and driving value creation.

Amgen reports revenue and earnings growth, eyes AI for innovation

Amgen's Q3 performance showed revenue and earnings growth, driven by strong global volume and record sales for key medicines. The company's pipeline progress and strategic focus on R&D highlight a commitment to innovation and future growth. While challenges exist around acquisition integration and market competition, Amgen is poised for continued success through the end of the decade and beyond.

Amgen reports record sales in Q4 2023, eyes rare diseases

Amgen's Q4 2023 performance was robust, driven by record sales and strategic acquisitions.
Despite short-term challenges like tax payments impacting cash flow, the company remains confident in its long-term growth trajectory.
Opportunities lie in expanding the rare disease portfolio, advancing R&D initiatives, and exploring new therapeutic areas.
Overall, Amgen's strong financials, diverse pipeline, and focus on innovation position it well for sustained growth and global impact.

Amgen reports strong Q1 growth, eyes new markets and innovations

Amgen's Q1 2024 performance reflects strong sales growth, financial resilience, and continued momentum in key product segments, positioning the company for future success.
Despite challenges in competitive differentiation, product launches, and regulatory complexities, Amgen's strategic strengths in innovation, manufacturing, and market expansion offer a solid foundation for growth.
The company's focus on addressing unmet medical needs, exploring new therapeutic areas, and advancing pipeline candidates underscores its commitment to driving patient impact and capturing market opportunities.
With a robust financial outlook, ongoing Phase III trials, and a proactive approach to product development, Amgen is well-positioned to achieve its revenue targets, drive innovation, and deliver value to shareholders.

Amgen reports strong Q2 earnings, eyes growth in diverse markets

Amgen's Q2 2024 earnings call highlighted robust revenue growth, strong sales performance, and promising pipeline developments across various therapeutic areas.
While facing challenges in market dynamics and product differentiation, Amgen's strategic focus on rare diseases and innovative therapies positions it well for future growth.
With a clear outlook on capital allocation, continued expansion in endocrinology, and opportunities in the obesity market, Amgen remains poised for sustained success.

Amgen reports strong Q3 earnings and outlines growth strategies

Amgen's Q3 2024 earnings call highlighted robust financial performance, progress in pipeline development, and strategic initiatives for future growth. With a strong revenue outlook and focus on innovation, Amgen remains well-positioned in the biopharmaceutical industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. It operates through Human Therapeutics segment. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

VanEck Vectors Biotech ETF

Biogen

Gilead Sciences

iShares Nasdaq Biotechnology ETF

SPDR S&P Biotech ETF

Let's take a look at some big biotechnological earnings releases to see if these will impact ETFs exposed to the space.

How Are Biotech ETFs Reacting to These Q3 Earnings Releases?

THOUSAND OAKS, Calif., Nov. 5, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the groundbreaking of its newest biomanufacturing plant, located in New Albany, Ohio.

Amgen Begins Construction On New Biomanufacturing Plant In Central Ohio

Broadcom

Darden Restaurants

Intel

Lockheed Martin

Principal Financial Group

Philip Morris

Restaurant Brands

Truist Financial

I present my top 10 High Yield dividend stocks to consider during the month of November.

Top 10 High Yield Dividend Stocks For November 2021

Cisco Systems

Dow Inc

Verizon

Verizon Communications Inc 5.9 % Notes 2014-15.2.54 Sr

It is hard to believe, but after a very positive double-digit year for stocks, only two months remain in 2021.

5 Hard-Hit Dow Stocks Have Monster Upside and Come With Great Dividends

Amgen boasts strong profitability, with gross profit and net income margins that significantly exceed the industry average. Eroding sales of established products due to lower volume and price pressure will be offset by a pipeline of branded and biosimilar products.

Amgen: Fairly Valued At This Point

Boeing

Chevron

Disney

Johnson & Johnson

Coca-Cola

Merck

Visa

Walgreens

"The Dow® [adds a stock] if the company has an excellent reputation, demonstrates sustained growth, and is of interest to a large number of investors. Sector representation is also a consideration." Thirty Dow stocks represent nine of eleven sectors. Dow tracks utilities as a separate index and omits real estate. Broker top ten target-estimated net gains ranged from 14.02%-29.15% topped by V 11/1/21.

Check Out Dogs Of The Dow For November Dividend Income

A proposed cap on out-of-pocket drug costs for Medicare recipients would improve patient access, but allowing the U.S. government health plan for seniors to negotiate prices could limit innovation, Amgen Inc Chief Executive Robert Bradway said in an interview.

Amgen CEO says U.S. Medicare out-of-pocket cap will improve access

Amgen (AMGN) beats Q3 estimates for both earnings and sales. It lowers the upper end of the sales guidance for 2021 while raising the earnings range.

Amgen (AMGN) Q3 Earnings Top, Sales View Tightened, Stock Down

Amgen Inc's (NASDAQ: AMGN) Q3 revenues increased 4% to $6.71 billion, slightly beating the consensus of $6.68 billion. The increase is driven by higher unit demand, partially offset by lower net selling prices.

Amgen Q3 Earnings Saved By Higher Volumes Despite Pricing Pressure On Some Drugs

Amgen, Inc. (AMGN) CEO Bob Bradway on Q3 2021 Results - Earnings Call Transcript

Amgen (AMGN) delivered earnings and revenue surprises of 10.66% and 0.13%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Amgen (AMGN) Q3 Earnings and Revenues Top Estimates

Amgen (NASDAQ:AMGN) reported its Q3 earnings results on Tuesday, November 2, 2021 at 04:00 PM. Here's what investors need to know about the announcement.

Amgen: Q3 Earnings Insights

Amgen Inc on Tuesday reported a 4% increase in third-quarter revenue as the impact of the COVID-19 pandemic on drug prescriptions began to ease, but said prices for some of its drugs remained under pressure from lower-cost competition.

Amgen 3rd quarter profit beats, sales rise 4%

THOUSAND OAKS, Calif., Nov. 2, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the third quarter of 2021.

Amgen Reports Third Quarter 2021 Financial Results

Amgen Inc. stock fell in the extended session Tuesday after the pharma company reported rising adjusted profit for the third quarter but said the pandemic-related gap in doctor's office visits and fewer people starting treatments continue to impact its business.

Earnings Results: Amgen still sees pandemic impact, with fewer patients starting treatments

Pfizer

Big Decisions from Outside the Market May Significantly Affect the Market

Pfizer And Amgen Release Earnings Today

Alibaba

Baidu

JD.com

McKesson

Reckitt Benckiser Group PLC

SPDR S&P 500 ETF Trust

Tencent Holdings Limited

The stock market in the United States is extremely overvalued but we can find bargains in other countries. Especially tech stocks in China seem extremely cheap and Great Britain is also presenting some picks.

Hunting For Bargains Again: 9 Picks

Volume growth of Amgen's (AMGN) key drugs like Prolia, Kyprolis, Repatha and others and biosimilars portfolio is expected to have been partially offset by biosimilar/generic competition for mature drugs.

Amgen (AMGN) to Report Q3 Earnings: What's in the Cards?

THOUSAND OAKS, Calif., Oct. 28, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that it will report its third quarter financial results on Tuesday, November 2, 2021, after the close of the U.S. financial markets.

Amgen Announces Webcast Of 2021 Third Quarter Financial Results

AbbVie

Fidelity MSCI Health Care ETF

iShares U.S. Healthcare ETF

Eli Lilly

UnitedHealth Group

Vanguard Health Care ETF

Health Care Select Sector SPDR Fund

The healthcare sector is expected to witness substantial earnings growth of 17.5% in the third quarter.

Healthcare ETFs in Focus as Q3 Earnings Unfold

THOUSAND OAKS, Calif., Oct. 26, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that it has been selected as one of the World's Best Workplaces™ for 2021 by Fortune magazine and Great Place to Work®.

Fortune and Great Place to Work® Name Amgen One of the World's Best Workplaces™ in 2021

Amgen (AMGN) closed the most recent trading day at $207.63, moving -0.77% from the previous trading session.

Amgen (AMGN) Stock Sinks As Market Gains: What You Should Know

THOUSAND OAKS, Calif., Oct. 21, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $1.76 per share dividend for the fourth quarter of 2021.

Amgen Announces 2021 Fourth Quarter Dividend

Cummins

Enbridge

The highest inflation in 30 years has some investors worried about soaring interest rates and a stagflationary recession triggering a bear market. The good news is that runaway inflation is not likely, due to several demographic megatrends.

3 Wide Moat Dividend Blue-Chip Buys In Case Inflation Starts To Fly

Amgen faces some issues similar to those faced by AbbVie.

News for Amgen Stock (AMGN)